DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Quinapril and Hydrochlorothiazide (Quinapril Hydrochloride / Hydrochlorothiazide) - Side Effects and Adverse Reactions



Quinapril hydrochloride and hydrochlorothiazide has been evaluated for safety in 1571 patients in controlled and uncontrolled studies. Of these, 498 were given quinapril plus hydrochlorothiazide for at least 1 year, with 153 patients extending combination therapy for over 2 years. In clinical trials with quinapril hydrochloride and hydrochlorothiazide, no adverse experience specific to the combination has been observed. Adverse experiences that have occurred have been limited to those that have been previously reported with quinapril or hydrochlorothiazide.

Adverse experiences were usually mild and transient, and there was no relationship between side effects and age, sex, race, or duration of therapy. Discontinuation of therapy because of adverse effects was required in 2.1% in patients in controlled studies. The most common reasons for discontinuation of therapy with quinapril hydrochloride and hydrochlorothiazide were cough (1%; see PRECAUTIONS) and headache (0.7%).

Adverse experiences probably or possibly related to therapy or of unknown relationship to therapy occurring in 1% or more of the 943 patients treated with quinapril plus hydrochlorothiazide in controlled trials are shown below.

  Percent of Patients in Controlled Trials
  Quinapril/ HCTZ N = 943   Placebo N = 100
Headache 6.7 30
Dizziness 4.8 4
Coughing 3.2 2
Fatigue 2.9 3
Myalgia 2.4 5
Viral Infection 1.9 4
Rhinitis 2 3
Nausea and/or Vomiting 1.8 6
Abdominal Pain 1.7 4
Back Pain 1.5 2
Diarrhea 1.4 1
Upper Respiratory Infection 1.3 4
Insomnia 1.2 2
Somnolence 1.2 0
Bronchitis 1.2 1
Dyspepsia 1.2 2
Asthenia 1.1 1
Pharyngitis 1.1 2
Vasodilatation 1 1
Vertigo 1 2
Chest Pain 1 2

Clinical adverse experiences probably, possibly, or definitely related or of uncertain relationship to therapy occurring in greater than or equal to 0.5% to less than 1% (except as noted) of the patients treated with quinapril/HCTZ in controlled and uncontrolled trials (N = 1571) and less frequent, clinically significant events seen in clinical trials or postmarketing experience (the rarer events are in italics) include (listed by body system):

BODY AS A WHOLE: Asthenia, Malaise
CARDIOVASCULAR: Palpitation, Tachycardia, Heart Failure, Hyperkalemia,
  Myocardial Infarction, Cerebrovascular Accident,
  Hypertensive Crisis, Angina Pectoris, Orthostatic
  Hypotension, Cardiac Rhythm Disturbance
GASTROINTESTINAL: Mouth or Throat Dry, Gastrointestinal Hemorrhage,
  Pancreatitis, Abnormal Liver Function Tests
NERVOUS/PSYCHIATRIC: Nervousness, Vertigo, Paresthesia
RESPIRATORY: Sinusitis, Dyspnea
INTEGUMENTARY: Pruritus, Sweating Increased, Erythema Multiforme,
  Exfoliative Dermatitis, Photosensitivity Reaction, Alopecia,
UROGENITAL SYSTEM: Acute Renal Failure, Impotence
OTHER: Agranulocytosis, Thrombocytopenia, Arthralgia
Angioedema: Angioedema has been reported in 0.1% of patients receiving
  quinapril (0.1%) (see WARNINGS).
Fetal/Neonatal Morbidity and See WARNINGS: Fetal/Neonatal
Mortality: Morbidity and Mortality

Postmarketing Experience

The following serious nonfatal adverse events, regardless of their relationship to quinapril and HCTZ combination tablets, have been reported during extensive postmarketing experience:

BODY AS A WHOLE: Shock, accidental injury, neoplasm, cellulitis, ascites, generalized edema, hernia and anaphylactoid reaction.

CARDIOVASCULAR SYSTEM: Bradycardia, cor pulmonale, vasculitis, and deep thrombosis.

DIGESTIVE SYSTEM: Gastrointestinal carcinoma, cholestatic jaundice, hepatitis, esophagitis, vomiting, and diarrhea.



MUSCULOSKELETAL SYSTEM: Myopathy, myositis, and arthritis.

NERVOUS SYSTEM: Paralysis, hemiplegia, speech disorder, abnormal gait, meningism, and amnesia.

RESPIRATORY SYSTEM: Pneumonia, asthma, respiratory infiltration, and lung disorder.

SKIN AND APPENDAGES: Urticaria, macropapular rash, and petechiases.

SPECIAL SENSES: Abnormal vision.

UROGENITAL SYSTEM: Kidney function abnormal, albuminuria, pyuria, hematuria, and nephrosis.

Quinapril monotherapy has been evaluated for safety in 4960 patients. In clinical trials adverse events which occurred with quinapril were also seen with quinapril hydrochloride and hydrochlorothiazide. In addition, the following were reported for quinapril at an incidence greater than 0.5%: depression, back pain, constipation, syncope, and amblyopia.

Hydrochlorothiazide has been extensively prescribed for many years, but there has not been enough systematic collection of data to support an estimate of the frequency of the observed adverse reactions. Within organ-system groups, the reported reactions are listed here in decreasing order of severity, without regard to frequency.

BODY AS A WHOLE: Weakness.
CARDIOVASCULAR: Orthostatic hypotension (may be potentiated by alcohol,
  barbiturates, or narcotics).
DIGESTIVE: Pancreatitis, jaundice (intrahepatic cholestatic), sialadenitis,
  vomiting, diarrhea, cramping, nausea, gastric irritation,
  constipation, and anorexia.
NEUROLOGIC: Vertigo, lightheadedness, transient blurred vision, headache,
  paresthesia, xanthopsia, weakness, and restlessness.
HEMATOLOGIC: Aplastic anemia, agranulocytosis, leukopenia,
  thrombocytopenia, and hemolytic anemia.
RENAL: Renal failure, renal dysfunction, interstitial nephritis
  (see WARNINGS).
METABOLIC: Hyperglycemia, glycosuria, and hyperuricemia.
HYPERSENSITIVITY: Necrotizing angiitis, Stevens-Johnson syndrome,
  respiratory distress (including pneumonitis and
  pulmonary edema), purpura, urticaria, rash, and

Clinical Laboratory Test Findings

Serum Electrolytes: See PRECAUTIONS.

Creatinine, Blood Urea Nitrogen: Increases (greater than 1.25 times the upper limit of normal) in serum creatinine and blood urea nitrogen were observed in 3% and 4%, respectively, of patients treated with quinapril hydrochloride and hydrochlorothiazide. Most increases were minor and reversible, which can occur in patients with essential hypertension but most frequently in patients with renal artery stenosis (see PRECAUTIONS).

PBI and Tests of Parathyroid Function: See PRECAUTIONS.

Hematology: See WARNINGS.

Other (causal relationships unknown): Other clinically important changes in standard laboratory tests were rarely associated with quinapril hydrochloride and hydrochlorothiazide administration. Elevations in uric acid, glucose, magnesium, cholesterol, triglyceride, and calcium (see PRECAUTIONS) have been reported.


Below is a sample of reports where side effects / adverse reactions may be related to Quinapril and Hydrochlorothiazide. The information is not vetted and should not be considered as verified clinical evidence.

Possible Quinapril and Hydrochlorothiazide side effects / adverse reactions in 69 year old female

Reported by a consumer/non-health professional from United States on 2012-04-16

Patient: 69 year old female weighing 65.8 kg (144.7 pounds)

Reactions: Dysphagia, Pharyngeal Oedema

Suspect drug(s):
Quinapril and Hydrochlorothiazide
    Administration route: Oral
    End date: 2011-05-02

Quinapril and Hydrochlorothiazide
    Administration route: Oral
    Start date: 2011-05-02
    End date: 2011-05-27

Quinapril and Hydrochlorothiazide
    Administration route: Oral
    Indication: Blood Pressure Increased
    Start date: 2011-05-02
    End date: 2011-05-27

Quinapril and Hydrochlorothiazide
    Administration route: Oral
    Indication: Blood Pressure Increased
    End date: 2011-05-02

Other drugs received by patient: Mirtazapine; Hydrocodone Bitartrate; Estradiol; Lipitor; Xanax

See index of all Quinapril and Hydrochlorothiazide side effect reports >>

Drug label data at the top of this Page last updated: 2010-05-06

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017